Haldol (Haloperidol)

Haloperidol, marketed as Haldol, is prescribed for the treatment of disorders characterized by excessive dopamine activity, particularly when rapid symptom control is required in both inpatient and outpatient settings.

• Schizophrenia: to reduce hallucinations, delusions, and thought disorder in chronic or acute phases.
• Acute psychotic episodes: for rapid stabilization of severe agitation or psychosis.
• Manic episodes of bipolar disorder: as an adjunct to mood stabilizers for acute mania.
• Tourette syndrome: to lessen motor and vocal tics when other therapies are insufficient.
• Severe agitation or aggression: in emergency or intensive care contexts to calm patients.

Haloperidol may cause side effects ranging from mild and transient to serious and potentially life‑threatening. Frequency depends on dose, duration, and individual factors, so regular monitoring is routine.

Common

• Drowsiness or sedation, usually early and may lessen over time.
• Extrapyramidal symptoms such as tremor, rigidity, or restlessness.
• Dry mouth and constipation, manageable with fluids and diet.
• Blurred vision or dizziness, especially on standing.
• Orthostatic hypotension, causing light‑headedness when standing quickly.

Serious

• Neuroleptic malignant syndrome: rare, life‑threatening fever, rigidity, autonomic instability.
• Tardive dyskinesia: potentially irreversible involuntary movements after long‑term use.
• Cardiac arrhythmias, including QT prolongation, which can lead to torsades de pointes.
• Severe depression or suicidal thoughts, though rare, require immediate evaluation.

When prescribing haloperidol, clinicians consider several precautions to minimize risk and ensure safe use.

• Assess for a history of cardiovascular disease, as haloperidol can affect heart rhythm.
• Evaluate for prior extrapyramidal reactions or movement disorders before initiating therapy.
• Use the lowest effective dose, especially in elderly patients, to reduce sedation and falls.
• Monitor for signs of neuroleptic malignant syndrome, particularly during dose escalation.
• Avoid abrupt discontinuation; taper gradually to prevent withdrawal or rebound psychosis.
• Check liver and kidney function periodically, as impairment may alter drug clearance.
• Review concomitant medications for QT‑prolonging potential to avoid additive cardiac risk.

Haloperidol can interact with other medicines, influencing its effectiveness or increasing adverse effects. Understanding key interactions helps clinicians manage therapy safely.

Avoid

• Combine with other dopamine antagonists or high‑potency antipsychotics, which may intensify extrapyramidal symptoms.
• Use with strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin) as they can raise haloperidol plasma levels.
• Co‑administration with QT‑prolonging drugs (e.g., quinidine, sotalol) may increase risk of cardiac arrhythmias.

Use with caution

• Concurrent use of benzodiazepines may enhance sedation; dose adjustments may be needed.
• Adding anticholinergic agents (e.g., benztropine) can help control extrapyramidal effects but may increase anticholinergic burden.
• Caution when given with opioids, as combined CNS depression can lead to respiratory depression.